Chimerix Inc.

7.88-0.3000-3.67%Vol 114.56K1Y Perf 390.57%
Apr 19th, 2021 11:37 DELAYED
BID7.85 ASK7.89
Open8.12 Previous Close8.18
Pre-Market- After-Market-
 - -%  - -
Target Price
15.25 
Analyst Rating
Moderate Buy 2.00
Potential %
93.77 
Finscreener Ranking
★★★★+     57.44
Insiders Trans % 3/6/12 mo.
-/-/-53 
Value Ranking
★★★+     54.65
Insiders Value % 3/6/12 mo.
-15/-15/-48 
Growth Ranking
★★★★+     63.85
Insiders Shares Cnt. % 3/6/12 mo.
-20/-20/-57 
Income Ranking
 —    -
Market Cap675.15M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
63.82 
Earnings Date
6th May 2021

Today's Price Range

7.778.21

52W Range

1.3711.57

5 Year PE Ratio Range

-2.50-2.80

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-3.20%
1 Month
-20.43%
3 Months
3.02%
6 Months
186.01%
1 Year
390.57%
3 Years
61.98%
5 Years
38.64%
10 Years
-

TickerPriceChg.Chg.%
CMRX7.88-0.3000-3.67
AAPL134.510.35000.26
GOOG2 296.74-1.0200-0.04
MSFT259.36-1.3800-0.53
XOM56.35-0.3100-0.55
WFC44.070.23000.52
JNJ162.490.25000.15
FB303.26-2.9200-0.95
GE13.33-0.0600-0.45
JPM153.08-0.2200-0.14
Financial StrengthValueIndustryS&P 500US Markets
9.30
9.60
0.04
0.04
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-332.40
-328.60
-1 118.30
-
RevenueValueIndustryS&P 500US Markets
4.13M
0.05
13.71
-1.80
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.20-0.195.00
Q03 2020-0.17-0.18-5.88
Q02 2020-0.18-0.1611.11
Q01 2020-0.15-0.17-13.33
Q04 2019-0.17-0.0664.71
Q03 2019-0.22-0.1531.82
Q02 2019-0.17-0.35-105.88
Q01 2019-0.35-0.350.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.5955.64Positive
6/2021 QR-0.2119.23Positive
12/2021 FY-0.7361.38Positive
12/2022 FY-0.33-65.00Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.59
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume114.56K
Shares Outstanding85.68M
Trades Count960
Dollar Volume9.47M
Avg. Volume1.14M
Avg. Weekly Volume322.69K
Avg. Monthly Volume511.18K
Avg. Quarterly Volume861.25K

Chimerix Inc. (NASDAQ: CMRX) stock closed at 8.18 per share at the end of the most recent trading day (a -1.56% change compared to the prior day closing price) with a volume of 350.73K shares and market capitalization of 675.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Chimerix Inc. CEO is Michael Sherman.

The one-year performance of Chimerix Inc. stock is 390.57%, while year-to-date (YTD) performance is 69.36%. CMRX stock has a five-year performance of 38.64%. Its 52-week range is between 1.37 and 11.57, which gives CMRX stock a 52-week price range ratio of 63.82%

Chimerix Inc. currently has a PE ratio of -12.30, a price-to-book (PB) ratio of 10.08, a price-to-sale (PS) ratio of 175.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.54%, a ROC of -36.93% and a ROE of -45.08%. The company’s profit margin is -%, its EBITDA margin is -328.60%, and its revenue ttm is $4.13 Million , which makes it $0.05 revenue per share.

Of the last four earnings reports from Chimerix Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Chimerix Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Chimerix Inc. is Moderate Buy (2), with a target price of $15.25, which is +93.77% compared to the current price. The earnings rating for Chimerix Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Chimerix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Chimerix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.70, ATR14 : 0.81, CCI20 : -110.49, Chaikin Money Flow : -0.10, MACD : -0.24, Money Flow Index : 39.43, ROC : -4.77, RSI : 48.67, STOCH (14,3) : 12.17, STOCH RSI : 0.60, UO : 38.95, Williams %R : -87.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Chimerix Inc. in the last 12-months were: David Jakeman (Option Excercise at a value of $12 338), David Jakeman (Sold 8 765 shares of value $50 667 ), Martha J. Demski (Option Excercise at a value of $122 108), Martha J. Demski (Sold 28 168 shares of value $91 869 ), Robert J. Meyer (Buy at a value of $49 840)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Chimerix Inc.

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia (or AML) and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.

CEO: Michael Sherman

Telephone: +1 919 806-1074

Address: 2505 Meridian Parkway, Durham 27713, NC, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

56%44%

Bearish Bullish

47%53%

Bearish Bullish

52%48%

News

Stocktwits